Optimizing Cancer-related Anemia Outcomes in the Community Setting: Interprofessional Approaches and Evidence-supported Strategies for Improving Care with Intravenous Iron

September 20, 2022

Target Audience

Hematologists/oncologists, primary care physicians, and their interprofessional team of nurses, nurse practitioners, physician assistants, and pharmacists who help manage patients with cancer.

Learning Objectives

  • Review the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches.
  • Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA), emphasizing the implications of CRA/CIA on oncologic outcomes and patient-centric metrics.
  • Appraise completed, ongoing, and planned clinical trials of IV iron products in CRA/CIA, highlighting the established ability of these agents to enhance hematopoietic response rates, decrease transfusion burden, and improve patient outcomes.
  • Discuss how next-generation IV iron products have dramatically improved upon the safety profiles of earlier generation agents, particularly with respect to severe hypersensitivity reactions.
  • Review current expert consensus guidelines for CRA/CIA management from ASCO/ASH, NCCN, and ESMO.  
  • Use real-world patient cases to evaluate evidence-supported strategies that members of the multidisciplinary and interprofessional cancer care team can use to safely and effectively implement IV iron into clinical practice.
  • Compare and contrast the unique clinical utility of currently-approved IV iron agents, emphasizing the impact of differential safety profiles on treatment decisions.
  • Investigate the clinical implications of IV iron-associated hypophosphatemia in all patients, but especially in those with cancer and/or those actively receiving chemotherapy.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from Pharmacosmos Therapeutics, Inc.

Additional Information

AttachmentSize
PDF icon Handout and References2.47 MB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 ICPE
  • 1.00 Participation
Course opens: 
07/14/2022
Course expires: 
10/20/2022
Event starts: 
09/20/2022 - 6:30pm EDT
Event ends: 
09/20/2022 - 7:30pm EDT
Rating: 
0

To register in advance click here: https://us06web.zoom.us/webinar/register/WN_lKoOwuI-SNueWb5e3lQiUw 

5 min     Welcome and Introductions/Pre-test

10 min     Setting the Stage: Understanding Iron Deficiency in the Context of Cancer-related Anemia

15 min     The Main Event: Harnessing Established and Emerging Evidence to Improve CRA/CIA Outcomes with Intravenous Iron

20 min     Ushering IV Iron into the Clinic: Practical Principles for the Multidisciplinary and Interprofessional Cancer Care Team

10 min     Conversations with the Experts/Audience Q&A/Post-test

Virtual Grand Rounds
United States

Jillian McInerney CRNP, AOCNP
Hematology, Medical Oncology
Pennsylvania Hospital
Philadelphia, PA

 

 


It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners:
Jeffrey A. Gilreath, PharmD–has disclosed that he was an advisor or consultant for American Regent.
Jillian McInerney CRNP, AOCNP–has no relevant financial relationships to disclose in relation to the content of this activity.

Planner/Faculty:
David Henry, MD–has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:
Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff/Planners:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-008-L01-P)

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 ICPE
  • 1.00 Participation
Please login or register to take this course.